MXCT Valuation
MaxCyte Inc
$
1.435
- Overview
- Forecast
- Valuation
- Earnings
MXCT Relative Valuation
MXCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MXCT is overvalued; if below, it's undervalued.
Historical Valuation
MaxCyte Inc (MXCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.85 is considered Undervalued compared with the five-year average of -17.60. The fair price of MaxCyte Inc (MXCT) is between 1.99 to 6.66 according to relative valuation methord. Compared to the current price of 1.44 USD , MaxCyte Inc is Undervalued By 27.95%.
Relative Value
Fair Zone
1.99-6.66
Current Price：1.44
27.95%
Undervalued
-2.98
PE
1Y
3Y
5Y
Trailing
Forward
-0.78
EV/EBITDA
MaxCyte Inc. (MXCT) has a current EV/EBITDA of -0.78. The 5-year average EV/EBITDA is -18.16. The thresholds are as follows: Strongly Undervalued below -68.90, Undervalued between -68.90 and -43.53, Fairly Valued between 7.22 and -43.53, Overvalued between 7.22 and 32.59, and Strongly Overvalued above 32.59. The current Forward EV/EBITDA of -0.78 falls within the Historic Trend Line -Fairly Valued range.
-0.59
EV/EBIT
MaxCyte Inc. (MXCT) has a current EV/EBIT of -0.59. The 5-year average EV/EBIT is -12.53. The thresholds are as follows: Strongly Undervalued below -44.41, Undervalued between -44.41 and -28.47, Fairly Valued between 3.42 and -28.47, Overvalued between 3.42 and 19.36, and Strongly Overvalued above 19.36. The current Forward EV/EBIT of -0.59 falls within the Historic Trend Line -Fairly Valued range.
3.85
PS
MaxCyte Inc. (MXCT) has a current PS of 3.85. The 5-year average PS is 13.10. The thresholds are as follows: Strongly Undervalued below -2.58, Undervalued between -2.58 and 5.26, Fairly Valued between 20.93 and 5.26, Overvalued between 20.93 and 28.77, and Strongly Overvalued above 28.77. The current Forward PS of 3.85 falls within the Undervalued range.
0.00
P/OCF
MaxCyte Inc. (MXCT) has a current P/OCF of 0.00. The 5-year average P/OCF is -24.70. The thresholds are as follows: Strongly Undervalued below -114.73, Undervalued between -114.73 and -69.72, Fairly Valued between 20.32 and -69.72, Overvalued between 20.32 and 65.34, and Strongly Overvalued above 65.34. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-4.09
P/FCF
MaxCyte Inc. (MXCT) has a current P/FCF of -4.09. The 5-year average P/FCF is -25.43. The thresholds are as follows: Strongly Undervalued below -99.50, Undervalued between -99.50 and -62.46, Fairly Valued between 11.61 and -62.46, Overvalued between 11.61 and 48.64, and Strongly Overvalued above 48.64. The current Forward P/FCF of -4.09 falls within the Historic Trend Line -Fairly Valued range.
MaxCyte Inc (MXCT) has a current Price-to-Book (P/B) ratio of 0.71. Compared to its 3-year average P/B ratio of 1.90 , the current P/B ratio is approximately -62.58% higher. Relative to its 5-year average P/B ratio of 2.73, the current P/B ratio is about -74.00% higher. MaxCyte Inc (MXCT) has a Forward Free Cash Flow (FCF) yield of approximately -27.19%. Compared to its 3-year average FCF yield of -7.11%, the current FCF yield is approximately 282.35% lower. Relative to its 5-year average FCF yield of -5.87% , the current FCF yield is about 362.94% lower.
0.71
P/B
Median3y
1.90
Median5y
2.73
-27.19
FCF Yield
Median3y
-7.11
Median5y
-5.87
Competitors Valuation Multiple
The average P/S ratio for MXCT's competitors is 4.94, providing a benchmark for relative valuation. MaxCyte Inc Corp (MXCT) exhibits a P/S ratio of 3.85, which is -22.06% above the industry average. Given its robust revenue growth of -18.43%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MXCT decreased by 68.06% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -89.89 to -145.26.
The secondary factor is the Revenue Growth, contributed -18.43%to the performance.
Overall, the performance of MXCT in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
HKD
AMTD Digital Inc
1.660
USD
-0.60%
FLWS
1-800-Flowers.Com Inc
5.720
USD
0.00%
UHT
Universal Health Realty Income Trust
39.429
USD
-0.21%
SBC
SBC Medical Group Holdings Inc
4.315
USD
0.00%
VERV
Verve Therapeutics Inc
11.200
USD
+0.27%
MATV
Mativ Holdings Inc
10.831
USD
-2.95%
FFWM
First Foundation Inc
5.370
USD
-2.19%
SHBI
Shore Bancshares Inc
16.190
USD
0.00%
PSBD
Palmer Square Capital BDC Inc
14.000
USD
+0.36%
DDI
DoubleDown Interactive Co Ltd
9.390
USD
0.00%
FAQ
Is MaxCyte Inc (MXCT) currently overvalued or undervalued?
MaxCyte Inc (MXCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.85 is considered Undervalued compared with the five-year average of -17.60. The fair price of MaxCyte Inc (MXCT) is between 1.99 to 6.66 according to relative valuation methord. Compared to the current price of 1.44 USD , MaxCyte Inc is Undervalued By 27.95% .
What is MaxCyte Inc (MXCT) fair value?
How does MXCT's valuation metrics compare to the industry average?
What is the current P/B ratio for MaxCyte Inc (MXCT) as of Aug 14 2025?
What is the current FCF Yield for MaxCyte Inc (MXCT) as of Aug 14 2025?
What is the current Forward P/E ratio for MaxCyte Inc (MXCT) as of Aug 14 2025?